U.S. STOCKS Autodesk, Aaron's Company
Eikon search string for individual stock moves: STXBZ
The Day Ahead newsletter: https://refini.tv/3LI4BU7
The Morning News Call newsletter: https://refini.tv/3dKUyB8
Futures tracking Wall Street's main indexes were mixed in muted trading on Monday as investors awaited fresh economic data and comments from Federal Reserve officials throughout the week for more clarity on monetary policy. .N
At 9:03 ET, Dow e-minis 1YMc1 were down 0.26% at 38,505. S&P 500 e-minis ESc1 were down 0.12% at 5,430.75, while Nasdaq 100 e-minis NQc1 were up 0.01% at 19,687.25.
The top three NYSE percentage gainers premarket .PRPG.NQ:
** Allego Nv Ord <ALLG.K>, up 129.9%
** The Aarns Co Ord <AAN>, up 32.2%
** Primo Water Ord <PRMW.K>, up 12.5%
The top three NYSE percentage losers premarket .PRPL.NQ:
** Belden Inc <BDC>, down 15.5%
** Ampco Pittsburgh <AP>, down 9.6%
** Cs Disco Inc Ord <LAW>, down 9.6%
The top three Nasdaq percentage gainers premarket .PRPG.O:
** Mustang Bio Inc <MBIO.O>, up 189.2%
** Company name not found <SCNI.O>, up 77.7%
** Interactive Strength Inc <TRNR.O>, up 60.3%
The top three Nasdaq percentage losers premarket .PRPL.O:
** Aerovate Therapeutics Inc <AVTE.O>, down 90.7%
** Ovid Therapeutics Inc <OVID.O>, down 65.3%
** Company name not found <OCEAW.O>, down 50%
** Autodesk Inc ADSK.O: up 4.6% premarket
BUZZ - Gains after report Starboard Value takes about $500 mln stake nL4N3IF0IZ
** Ollie's Bargain Outlet Holdings Inc OLLI.O: up 2.8% premarket
BUZZ - Up after JP Morgan upgrades to 'overweight' nL4N3IF0M2
** Fate Therapeutics Inc FATE.O: up 6.6% premarket
BUZZ - Piper Sandler raises Fate to 'overweight' on disease treatment progress nL4N3IF0MO
** Aaron's Company Inc AAN.N: up 32.2% premarket
BUZZ - Jumps on take-private deal with IQVentures nL4N3IF0NT
** Rio Tinto PLC RIO.N: down 1.5% premarket ** BHP Group Ltd BHP.N: down 2.1% premarket ** Southern Copper Corp SCCO.N: down 1.9% premarket ** Freeport-McMoRan Inc FCX.N: down 1.4% premarket BUZZ - US shares of copper miners fall after weak Chinese factory data nL4N3IF0OA
** Marinus Pharmaceuticals Inc MRNS.O: down 8.5% premarket
BUZZ - Down after seizure treatment fails to meet a key late-stage study goal nL4N3IF0O7
** AMC Networks Inc AMCX.O: down 12.2% premarket
BUZZ - Slides on convertible debt deal plans nL1N3IF0AG
** Ovid Therapeutics Inc OVID.O: down 65.3% premarket
BUZZ - Plummets after Takeda's drug fails in late-stage studies nL4N3IF0P9
** Zymeworks Inc ZYME.O: up 6.4% premarket
BUZZ - Gains on FDA nod for study of cancer therapy in humans nL4N3IF0SO
** Best Buy Co Inc BBY.N: up 4.0% premarket
BUZZ - Rises after report UBS turns bullish nL1N3IF0CK
(Compiled by Rajarshi Roy and Abhinav Parmar)
</body></html>Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
